



INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

PTO Form 1449

Attorney Docket 044508-5008

Application No. 10/578,438

Applicants: Ajay Verma *et al.*

Page 1 of 2

Filing Date: May 5, 2006

Group Art Unit: Unassigned

U.S. PATENT DOCUMENTS

Initial	Document No.	Date	Name	Class	Sub-Class	Filing Date
1.	6,222,015	04/24/2001	Wilkinson	530	350	08/25/1998

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

/T.L./	2.	Albina <i>et al.</i> (2001), HIF-1 expression in healing wounds: HIF-1a induction in primary inflammatory cells by TNF-alpha. <i>Am. J. Physiol. Cell Physiol.</i> 281(6): C1971-7
	3.	Anzellotti <i>et al.</i> (2000), Novel flavonol 2-oxoglutarate dependent dioxygenase: affinity purification, characterization, and kinetic properties. <i>Arch Biochem Biophys.</i> 382(2):161-72.
	4.	Bruick <i>et al.</i> (2001), A conserved family of prolyl-4-hydroxylases that modify HIF. <i>Science.</i> 294(5545):1337-40
	5.	Cerbon-Ambriz <i>et al.</i> (1987), Lactate and pyruvate increase the incorporation of [3H]proline into collagen [3H]hydroxyproline in liver slices of CCl4 cirrhotic rats. <i>Lab Invest.</i> 57(4):392-6.
	6.	Chang <i>et al.</i> (2003), Pyruvate inhibits zinc-mediated pancreatic islet cell death and diabetes. <i>Diabetologia.</i> 46(9):1220-7.
	7.	Cramer <i>et al.</i> (2003), A novel role for the hypoxia inducible transcription factor HIF-1alpha: critical regulation of inflammatory cell function. <i>Cell Cycle.</i> 2(3):192-3.
	8.	Fink (2003) Ethyl pyruvate: a novel anti-inflammatory agent. <i>Crit Care Med.</i> 31(1 Suppl):S51-6
	9.	Hanauske-Abel <i>et al.</i> (2003), The HAG mechanism: a molecular rationale for the therapeutic application of iron chelators in human diseases involving the 2-oxoacid utilizing dioxygenases. <i>Curr Med Chem.</i> 10(12):1005-19
	10.	Hawaleshka <i>et al.</i> (1998), Ischaemic preconditioning: mechanisms and potential clinical applications <i>Can J Anaesth.</i> 45(7):670-82.
	11.	Ivan <i>et al.</i> (2002), Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. <i>Proc Natl Acad Sci U S A.</i> 99(21):13459-6
	12.	Jensen <i>et al.</i> (1986), Effect of lactate, pyruvate, and pH on secretion of angiogenesis and mitogenesis factors by macrophages. <i>Lab Invest.</i> 54(5): 574-8
	13.	Jones <i>et al.</i> (2001), Hypoxic preconditioning induces changes in HIF-1 target genes in neonatal rat brain. <i>J Cereb Blood Flow Metab.</i> 21(9):1105-14
	14.	Kaule <i>et al.</i> (1998), Prolyl hydroxylase activity in tissue homogenates of annelids from deep sea hydrothermal vents. <i>Matrix Biol.</i> 17(3):205-12.
	15.	Knowles <i>et al.</i> (2003), Effect of ascorbate on the activity of hypoxia-inducible factor in cancer cells. <i>Cancer Res.</i> 63(8):1764-8.
	16.	Koritzinsky <i>et al.</i> (2001), Cell cycle progression and radiation survival following prolonged hypoxia and re-oxygenation, <i>Int. J. Radiat. Biol.</i> 77(3): 319-328.
	17.	Lee <i>et al.</i> (2001), Angiogenic activity of pyruvic acid in in vivo and in vitro angiogenesis models. <i>Cancer Res.</i> 61(8):3290-3.
	18.	Lu <i>et al.</i> (2002), Hypoxia-inducible Factor-1 Activation by Glycolysis Implicates the Warburg Effect in Carcinogenesis, <i>J. Biol. Chem.</i> 277: 23111-23115.
/T.L./	19.	Ng. <i>et al.</i> (1991), Cosubstrate Binding Site of Pseudomonas sp, AK1 g-Butyrobetaine Hydroxylase <i>J. Biol. Chem</i> 266(3): 1526-1533.

Examiner

/Trevor Love/

Date Considered

01/05/2009

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) PTO Form 1449		Attorney Docket 044508-5008	Application No. 10/578,438
		Applicants: Ajay Verma <i>et al.</i>	Page 2 of 2
		Filing Date: May 5, 2006	Group Art Unit: Unassigned
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)			
/T.L./	20.	Ruscher <i>et al.</i> (2002), Erythropoietin is a paracrine mediator of ischemic tolerance in the brain: evidence from an in vitro model. J Neurosci. 22(23):10291-301.	
↓	21.	Sawyer (1995), Practical applications of neuronal tissue culture in in vitro toxicology. Clin Exp Pharmacol Physiol. 22(4):295-6.	
↓	22.	Scheid <i>et al.</i> (2000), Hypoxia-regulated gene expression in fetal wound regeneration and adult wound repair. Pediatr Surg Int. 16(4): 232-6	
↓	23.	Semenza G.L. (2001), Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology. Trends Mol Med. 7(8):345-50.	
/T.L./	24.	Warnecke <i>et al.</i> (2003), Activation of the hypoxia-inducible factor-pathway and stimulation of angiogenesis by application of prolyl hydroxylase inhibitors. FASEB J. 17(9):1186-8.	
Examiner /Trevor Love/		Date Considered 01/05/2009	
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			